Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microbiota agents. We focus on pharmaceutical research in the therapeutic fields of antiviral, hematology, oncology, immunology, and digestion.
At present, our main products include the recombinant protein therapeutics "Recombinant Human Erythropoietin (EPOSINO)", "Recombinant Human Interferon α1b (SINOGEN)" and "Recombinant Human Granulocyte Colony-stimulating Factor (WHITE-C)", as well as the microecological agent "Combined Clostridium Butyricum and Bifidobacterium (CHANG LEKANG)".
In recent years, we have achieved continued and rapid growth in its business, becoming a leader in the recombinant protein therapeutics industry. Our core products, remained at the forefront of similar varieties in China, have been adopted by over 16,000 sales terminals, including over 6,000 hospitals in the provinces, municipalities and regions across China, and accessed into and sold in over 30 countries, including Brazil, Philippines and Indonesia.
With over two decades of accumulation in pharmaceutical R&D and industrialization, we have established a complete system of pharmaceutical R&D innovation, covering pharmaceutical innovation capabilities from pharmaceutical discovery, pharmaceutical research, preclinical research and clinical research to industrialized production. Depending on prokaryotic cell technology, eukaryotic cell technology and viable bacteria technology, we have built 5 world-leading technology platforms, including strain platform, recombinant protein therapeutics industrialization platform, microecological agent R&D and industrialization platform, recombinant protein secretion and expression platform and long-acting recombinant protein platform. At present, we have obtained 38 patents, with 9 biopharmaceutical projects under research, including 3 projects of new biopharmaceuticals.
Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology, becoming the leader of high quality biologicals.
| Full name | SHAN DONG KEXING BIOPRODUCTS CO., LTD |
|---|---|
| Abbreviations | Kexing Biopharm |
| Code | 688136 |
| Founded | 1997-8-22 |
| Listing | 2020-12-14 |
| Domicile | Jinan, Shandong province of China |
| Website | http://www.kexing.com/ |
| ir@kexing.com | |
| STAR Theme | Biomedicine |
| CSRCSector | Manufacturing |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.93 | 1.07 | 1.54 |
| R&D expenditure as a % of operating revenue | 4.93% | 3.88% | 4.79% |
| Operating Revenue | 1,220.29 | 1,190.77 | 890.61 |
| Net Income | 139.14 | 159.81 | 94.16 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 1,220.29 | 1,190.77 | 890.61 |
| Operating Costs | 1,059.52 | 993.48 | 771.04 |
| Operating Income | 159.85 | 188.98 | 121.27 |
| Pretax Income | 159.16 | 187.78 | 121.27 |
| Income Tax | 20.02 | 27.97 | 27.10 |
| Net Income | 139.14 | 159.81 | 94.16 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,643.92 | 648.30 | 469.22 |
| Non-current Assets-Total | 722.69 | 531.71 | 385.11 |
| Total Assets | 2,366.62 | 1,180.01 | 854.33 |
| Liabilities | |||
| Current Liabilities-Total | 440.70 | 440.39 | 300.62 |
| Non-current Liabilities-Total | 95.79 | 43.28 | 59.25 |
| Total Liabilities | 536.50 | 483.67 | 359.87 |
| Stockholder's Equity | |||
| Share Capital | 1,464.93 | 470.29 | 249.06 |
| Retained Profits | 365.19 | 226.05 | 245.40 |
| Total Owners' Equity | 1,830.12 | 696.34 | 494.46 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 105.93 | 5.25 | 63.44 |
| Net Cash Flows-Investing | -200.55 | -53.59 | -197.87 |
| Net Cash Flows-Financing | 1,035.97 | 152.24 | 114.98 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 深圳科益医药控股有限公司 | 131.78 | 66.32% |
| 深圳市恒健企业管理合伙企业（有限合伙） | 9.23 | 4.65% |
| 深圳市裕早企业管理合伙企业（有限合伙） | 8.02 | 4.03% |
| 长江财富－科兴制药员工战略配售集合资产管理计划 | 4.97 | 2.50% |
| 中信建投投资有限公司 | 1.71 | 0.86% |
| 龚雨飞 | 1.33 | 0.67% |
| 新火炬科技有限公司 | 0.55 | 0.28% |
| 刘锦标 | 0.22 | 0.11% |
| 付婉 | 0.21 | 0.10% |
| 皓熙股权投资管理（上海）有限公司 | 0.19 | 0.10% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.